# Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC

> **NCT04723004** · PHASE3 · UNKNOWN · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 326 (actual)

## Conditions studied

- Advanced Hepatocellular Carcinoma (HCC)

## Interventions

- **COMBINATION_PRODUCT:** Toripalimab combined with Bevacizumab
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT04723004
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-15
- **Primary completion:** 2023-10-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 326 (ACTUAL)
- **Last updated:** 2023-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04723004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04723004, "Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04723004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*